Pasar al contenido principal

Main navigation

  • Sobre El ITEFI
  • Investigación
  • Formación y empleo
  • OpenLab
  • Servicios científico técnicos
  • Directorio

Ultrasound Technology as a Novel Treatment Strategy in Pancreatic Cancer

Luis M Rodríguez-Lorenzo, Alberto Pinto del Corral, Luis Hernández, Jesús Frutos Díaz-Alejo, Vanessa Pachón Olmos, Cristian Perna, Julie Earl
Nov Appro in Can Study, 2019, 2(5). NACS.000550.2019
https://doi.org/10.31031/NACS.2019.02.000550

Opinion. Adenocarcinoma of the pancreas (PDAC) accounts for 2.4% of all cancers diagnosed and is the fourth leading cause of cancer death, with almost equal rates of incidence and mortality [1]. By 2030, pancreatic cancer is projected to be the second leading cause of cancer-related death [2], surpassing breast, prostate and colorectal cancer. The overall survival at 5 years of around 7.2% as the majority of patients present with advanced disease at diagnosis. Patients with localized disease are treated with surgery, with or without neoadjuvant chemotherapy/ radiotherapy, followed by adjuvant chemotherapy. The majority (around 80%) of patients are treated only with chemotherapy as they have an advanced disease. Patients are treated in the first line with gemcitabine-abraxane or Folfirinox and with Naliri plus 5FU in the second line. There have been few clinical advances in PDAC treatment over the last 20 years and chemotherapy is the only treatment option available for the majority of patients. These tumours are also resistant to many targeted therapies such as anti-EGFR therapy like cetuximab [3] due to the presence of a KRAS mutation in the majority of primary tumors. Personalized medicine strategies have not yet been established in pancreatic cancer as in other more common tumour types. Thus, novel anti-tumour strategies are an important clinical need in order to improve survival rates.

Acknowledgement

We would like to acknowledge the following funding related with the use of ultrasounds as a novel therapeutic strategy: Spanish National Plan project RETOS DPI 2017-90147-R. Intramural call for new research projects for clinical researchers and emerging research groups. IRYCIS. (2018/0240). Iberoamerican Network CYTED-DITECROD-218RT0545.

RESULT
GSTU

proyecto/s relacionado/s

  • Low intensity ultrasounds for early detection and modulation of tumor and stroma
    Programa Estatal de I+D+i Orientada a los Retos de la Sociedad (AEI), Fondos Feder
Departamento de Acústica y Evaluación No Destructiva (DAEND)
  • GAA: Grupo de Acústica ambiental
  • G CARMA: Grupo de Caracterización de materiales mediante evaluación no destructiva
  • ULAB: Ultrasonidos para el análisis de líquidos y bioingeniería
Departamento de Tecnologías de la Información y Las Comunicaciones (DTIC)
  • GiCP: Grupo de investigación en Ciberseguridad y Protección de la Privacidad
  • GICSI: Grupo de investigación en Criptología y Seguridad de la Información
    • LCQE: Laboratorio de Comunicaciones Cuánticas
  • PSUM: Grupo de Procesamiento de Señal en sistemas Ultrasónicos Multicanal
Departamento de Sensores y Sistemas Ultrasónicos (DSSU)
  • GSTU: Grupo de Sistemas y tecnologías ultrasónicas
  • NoySI: Grupo de Nanosensores y Sistemas Inteligentes
  • RESULT: Resonadores ultrasónicos para cavitación y micromanipulación
  • SENSAVAN: Grupo de Tecnología de Sensores Avanzados
  • QE: Electrónica Cuántica
Laboratorios
  • Laboratorio de Acústica
  • Laboratorio de Metrología Ultrasónica Médica (LMUM)
  • Laboratorio de Comunicaciones Cuánticas
  • Laboratory for International Collaboration in Advanced Biophotonics Imaging

Instituto de Tecnologías Físicas y de la Información Leonardo Torres Quevedo  - ITEFI
C/ Serrano, 144. 28006 - Madrid • Tel.: (+34) 91 561 88 06  Contacto  •  Intranet
EDIFICIO PARCIALMENTE ACCESIBLE POR PERSONAS CON MOVILIDAD REDUCIDA